Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to -$10000.0.

  • OptimizeRx's Cash from Investing Activities rose 8913.04% to -$10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$258000.0, marking a year-over-year increase of 9902.02%. This contributed to the annual value of -$450000.0 for FY2024, which is 9822.39% up from last year.
  • Latest data reveals that OptimizeRx reported Cash from Investing Activities of -$10000.0 as of Q3 2025, which was up 8913.04% from -$44000.0 recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Cash from Investing Activities registered a high of $3.2 million during Q2 2023, and its lowest value of -$37.5 million during Q3 2022.
  • Its 5-year average for Cash from Investing Activities is -$4.5 million, with a median of -$120000.0 in 2024.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 2242542.61% in 2022, then soared by 25201.52% in 2023.
  • Over the past 5 years, OptimizeRx's Cash from Investing Activities (Quarter) stood at -$99021.0 in 2021, then plummeted by 18567.26% to -$18.5 million in 2022, then plummeted by 40.66% to -$26.0 million in 2023, then soared by 99.54% to -$120000.0 in 2024, then surged by 91.67% to -$10000.0 in 2025.
  • Its last three reported values are -$10000.0 in Q3 2025, -$44000.0 for Q2 2025, and -$84000.0 during Q1 2025.